ReviewFrontiers in pharmacology2026
Research progress on glioma drug resistance: mechanism analysis and therapeutic strategies.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma, especially glioblastoma multiforme (GBM), has become one of the major clinical challenges in the field of neurooncology due to its high invasiveness and significant multidrug resistance (MDR). The mechanism of drug resistance is complex and involves the synergy of many factors, including the overexpression of MDR related transporters such as P-glycoprotein (P-gp), multidrug resistance associated protein 1 (MRP1) and breast cancer resistance protein (BCRP), the characteristics of tumor stem cells, and the influence of tumor microenvironment (especially hypoxia). In addition, abnormally activated signaling pathways (such as Hippo pathway), abnormal regulation of non coding RNA and mitochondrial dysfunction also contribute to treatment failure. This article reviews the molecular research progress in the mechanism of drug resistance in glioma in recent years, focusing on the dynamic regulation of MDR protein, the drug resistance mediated by tumor stem cells, the impact of tumor microenvironment on drug efficacy, and the role of signaling pathways and non coding RNA in the development of drug resistance. At the same time, this paper also discusses the emerging strategies of drug delivery system and combination therapy based on nanotechnology. Through the systematic integration of existing studies, the aim is to deeply analyze the mechanism of drug resistance, provide theoretical basis and direction for the development of more effective treatment, and ultimately help improve the clinical prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.